Designing proteins that work using recombinant technologies.

Designing proteins that work using recombinant technologies. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Designing proteins that work using recombinant technologies. Abstract Text:

Therapeutic proteins have been engineered for a variety of purposes including reduced antigenicity, longer half-life, simplified process development, and increased affinity. Fusion proteins bring together functions from two different molecules creating therapeutics with completely novel activities. Protein engineering technologies have relied on rational design, directed evolution, DNA shuffling, RNA-peptide fusion, phage and ribosomal display methods to select out candidate protein forms with the desired therapeutic properties. Engineered site-specific pegylation and glycosylation strategies have improved circulation half-life, reduced immunogenicity and increased protein therapeutic stability. In this review we describe how protein engineering techniques have been used to select out, improve stability and clinical efficacy of protein therapeutics.

Designing proteins that work using recombinant technologies. Publishing Authors By Initials

For similar investigative techniques: technology, pharmaceutical research abstracts see: investigative techniques: technology, pharmaceutical research

PUBMED ID PMID:

MEDLINE DATE:

Designing proteins that work using recombinant technologies. Journal Published:

PUBLICATION TYPE: Review

Journal: Current pharmaceutical biotechnology

VOLUME: 3

Page Numbers: 285-97

Journal Abbreviation: Curr Pharm Biotechnol

ISSN: 1389-2010

DAY: 12

MONTH: Dec

YEAR: 2002

Designing proteins that work using recombinant technologies. Information

Number of References: 83

LANGUAGE: eng

NlmUniqueID: 100960530

Designing proteins that work using recombinant technologies. Keywords Mesh Terms:

KEYWORDS: Technology, Pharmaceutical

MESH TERMS: methods

Chemical & Substance for Abstract: Designing proteins that work using recombinant technologies. Information

Substance Name: Recombinant Proteins

Registry Number: 0

Grant and Affiliation Information for Designing proteins that work using recombinant technologies.

AFFILIATION: Dendreon Corporation, 3005 First Avenue, Seattle, WA 98121, USA.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Pharm Biotechnol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Designing proteins that work using recombinant technologies Related Publications

• Chimpanzees as fauna: comparisons of sympatric large mammals across long-term study sites.
• Designing proteins that work using recombinant technologies.
• Hydrogenolysis of 2,3,3-trimethyl-l-butanol.
• Kinji Imanishi and 60 years of Japanese primatology.
• Phylogenetic analyses of behavior support existence of culture among wild chimpanzees.
• Savanna chimpanzees dig for food.
• The nature of culture: Technological variation in chimpanzee predation on army ants revisited.